Business & Regulation

Features

Joe Biden’s global corporation tax deal: A prediction on what’s next

Why have the nations of the world agreed to a new minimum corporation tax rate? And what happens to so-called "Google taxes" now?

Features

Regulatory roundup: BMS’s T lymphocyte immunotherapy tripped by lung cancer trial termination

Features

Regulatory roundup: Ology, MaxCyte make moves in women’s cancer with divergent approval chances

Features

Multiple myeloma: first bispecific mAb to secure r/r approval will have biggest market bite

Features

Regulatory roundup: Akeso’s bispecific antibody moves closer to approval in China

Features

Novavax Covid-19 vaccine booster: safety and manufacturing questions remain

Features

Regulatory roundup: Alexion ALS drug sees approval prospects plummet

Features

Gilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravir

Features

Akebia and GSK will grapple with heightened scrutiny of HIF PHIs after roxadustat concerns

Features

Regulatory roundup: Servier, Pfizer and Debiopharm gather gains with oncology trial updates; Karyopharm poses a loss

Features

Race to develop mRNA flu vaccines will contend with a longer review than Covid-19

Features

After Covid-19, mRNA technology aims to revolutionise the flu shot

Features

BioMarin’s growth-accelerating drug for dwarfism will face scrutiny from European payers

Features

Medicare’s National Coverage Determination could boost chances of limited Aduhelm coverage despite backlash

Comment

Setback for Kyowa’s Nouryant in European Parkinson’s disease market – register for free webinar

GlobalData Healthcare

News

Business optimism declines marginally in May: Poll

Features

IoT must become the Internet of Secure Things for widescale acceptance in the 5G era